Role of Interleukin-13 Pathways on Pain and Itch Sensitivity
Key facts
- Where
- Aalborg and Gistrup, DenmarkSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06503510, who can take part
Where in Denmark
- Aalborg UniversityAalborg, DenmarkNot yet recruiting
- Aalborg UniversityGistrup, DenmarkTaking people
- CNAPGistrup, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aalborg University
- Trial code
- NCT06503510
- Record updated
- 9 November 2026
- Original description
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.Read full original descriptionShow less
The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Inclusion: Healthy men and women; 18-60 years.
Exclusion: Drug addiction defined as any use of cannabis, opioids, or other drugs; Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.); Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment); Use of systemic and topical corticosteroids; Pregnancy or lactation; Moles, wounds, scars, or tattoos in the area to be treated or tested; Consumption of alcohol or painkillers 24 hours before the study days and between these; Acute or chronic pain; Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials); Lack of ability to cooperate.